Loading quotes...

Forecast

The analysts' average price target is €426.59 (+2.15%). The median is €433.40 (+3.78%).

Buy
  19
Hold
  16
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Waters seen by Morgan Stanley as best positioned by China's new lab price framework

    Morgan Stanley rates Waters as a winner from China’s final pricing framework for clinical laboratory services due to its position in mass spectrometry and more complex microbiological workflows. The framework, published by the National Healthcare Security Administration, retains a method-neutral structure, provides differentiated treatment and specific add-ons for mass spectrometry, and sets out more detailed rules for microbiology services. Danaher, Beckman Coulter and Thermo Fisher will be affected differently: Danaher faces limited risks to parts of its business, Beckman Coulter is under pressure in routine chemistry and immunoassays, and Thermo Fisher is less affected because of its portfolio structure and recent sales. » More on de.investing.com


  • Waters Corporation reaches 52‑week high at $420.3

    Shares of Waters Corporation rose to a 52‑week high of $420.3 and are currently trading at $420.77, with a market capitalization of $41.3 billion. Year‑to‑date the stock is up 44.4%. In the second quarter the company beat expectations with adjusted earnings of $3.05 per share (estimate $3.01) and revenue of $1.64 billion (estimate $1.62 billion), but it faces currency headwinds and integration challenges. TD Cowen has upgraded the stock to Buy and raised the price target to $475, while analysts also warn of potential overvaluation. » More on de.investing.com


  • Waters beats Q2 forecasts and raises full-year outlook, stock slightly down premarket

    Waters reported adjusted EPS of $3.05 for Q2 (expectation $3.01) and revenue of $1.645 billion (expectation $1.62 billion). Management raised the full-year guidance for organic revenue growth to 7–9% and adjusted EPS to $14.45–14.65, supported by cost reductions, price increases and product launches. Premarket the stock fell about 1.3% as investors weighed currency effects, acquisition-related charges and the complexity of integrating acquired businesses. Risks remain from currency headwinds, integration efforts and execution of planned price increases. » More on de.investing.com


  • Waters introduces Xevo TQ Absolute XR IVD mass spectrometer for clinical diagnostics

    Waters unveiled the Xevo TQ Absolute XR IVD at the 2026 annual meeting of the Association for Diagnostics & Laboratory Medicine, an LC‑MS/MS system for applications in women’s health, cancer diagnostics and toxicology. According to the company, the device offers up to fivefold greater sensitivity compared with similar systems (Xevo TQ-XS IVD and SCIEX 6500 IVD), enabling lower limits of detection and measurements from smaller sample volumes. The system uses the StepWave XR Ion Guide, which is said to deliver up to six times longer consistency of the ion ratio compared with the previous model, and is part of the MassTrak IVD portfolio including ACQUITY UPLC I-Class PLUS. Waters cites improved signal stability, robustness and potentially lower downtime; the system is now available to order. » More on de.investing.com


  • Waters brings coin-cell calorimeter for battery safety tests

    Waters Corporation has introduced the Waters TA Instruments Coin Cell Differential Scanning Calorimeter, which simultaneously captures thermal, electrochemical and gas-evolution data from fully assembled coin cells. The system provides voltage monitoring plus charge/discharge functionality, a temperature range from -80 °C to 600 °C, and can be coupled with MS, FTIR or GC‑MS for gas analysis. According to the company, the capsule-like design reduces sample preparation by more than 90%. Orders are available now, with deliveries expected to begin in August 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 1996, Waters has already paid €0.0316 in dividends. The last payout was in November 1996.

Financials

In the last quarter, Waters had revenue of €1.57bn and net profit of €71.94m
(EUR) October 2026
YoY
Revenue 1.57bn 129.60%
Gross profit 788.68m 95.51%
Net profit 71.94m 43.47%
EBITDA 379.24m 77.93%

Fundamentals

Metric Value
Market capitalization
€41.06bn
Number of shares
98.29m
52-week high/low
€438.69 - €256.65
Dividends No
Beta
1.15
P/E ratio
195.85
PEG ratio
-2.50
P/B ratio
2.96
P/S ratio
8.06

Company profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.

Name
Waters
CEO
Udit Batra
Headquarters Milford, ma
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
17/11/1995
Employees 15,000

Ticker symbols

Exchange Symbol
NYSE
WAT
London Stock Exchange
0LTI.L
Frankfurt
WAZ.F
Düsseldorf
WAZ.DU
London
0LTI.L
SIX
WAZ.SW
München
WAZ.MU
🍪

Parqet  uses cookies. Learn more